---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-276640"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:33:47.435093+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics reports Q3 loss; FDA requires new avasopasem trial; GRECO trials halted

## Summary
- FDA issued Complete Response Letter for avasopasem NDA; requires an additional Phase 3 trial for resubmission.
- GRECO-2 (pancreatic cancer) and GRECO-1 (NSCLC) trials halted following futility analyses.
- Workforce reduced by 22 employees (~70%) in August 2023; restructuring charges of $2.3M in Q3.
- Q3 2023 net loss of $15.1M ($0.33 per share) vs. $16.0M ($0.60) in Q3 2022; cash $28.4M.
- Company exploring strategic alternatives including mergers, asset sales; may be required to cease operations.

## SEC filing metadata
- accession: 0001193125-23-276640
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312523276640/0001193125-23-276640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312523276640/d596085d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-276640
- JSON: https://secwatch.observer/filing/0001193125-23-276640.json
- Plain text: https://secwatch.observer/filing/0001193125-23-276640.txt

## Key facts
- Earnings Releases
  Galera Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income $(15.1) million, EPS $(0.33) per share.
  - Period: third quarter ended September 30, 2023
  - Net income: $(15.1) million
  - EPS: $(0.33) per share
  - Result: reported results
  source text: Galera reported a net loss of $(15.1) million, or $(0.33) per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312523276640/0001193125-23-276640-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.